866-997-4948(US-Canada Toll Free)

Type 2 Diabetes Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 432 Pages


Global Markets Directs, \'Type 2 Diabetes Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 2 Diabetes. 

Type 2 Diabetes Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Type 2 Diabetes.
  • A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Type 2 Diabetes pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 13
Introduction 14
Global Markets Direct Report Coverage 14
Type 2 Diabetes Overview 15
Therapeutics Development 16
An Overview of Pipeline Products for Type 2 Diabetes 16
Type 2 Diabetes Therapeutics under Development by Companies 18
Type 2 Diabetes Therapeutics under Investigation by Universities/Institutes 32
Late Stage Products 34
Comparative Analysis 34
Mid Clinical Stage Products 35
Comparative Analysis 35
Early Clinical Stage Products 36
Comparative Analysis 36
Discovery and Pre-Clinical Stage Products 37
Comparative Analysis 37
Type 2 Diabetes Therapeutics Products under Development by Companies 38
Type 2 Diabetes Therapeutics Products under Investigation by Universities/Institutes 63
Companies Involved in Type 2 Diabetes Therapeutics Development 64
Bristol-Myers Squibb Company 64
Johnson & Johnson 65
Boehringer Ingelheim GmbH 66
F. Hoffmann-La Roche Ltd. 67
Shionogi & Co., Ltd. 68
Medinox, Inc. 69
Amgen Inc. 70
Sanofi-Aventis 71
Eli Lilly and Company 72
GlaxoSmithKline plc 73
MedImmune LLC 74
Isis Pharmaceuticals, Inc. 75
Gilead Sciences, Inc. 76
Daiichi Sankyo Company, Ltd 77
Merck & Co., Inc. 78
Dainippon Sumitomo Pharma Co., Ltd. 79
Taisho Pharmaceutical Co., Ltd. 80
Euroscreen S.A. 81
Novo Nordisk A/S 82
Generex Biotechnology Corporation 83
Takeda Pharmaceutical Company Limited 84
FibroGen, Inc. 85
Ipsen S.A. 86
Senexis Limited 87
Nycomed International Management GmbH 88
Neurocrine Biosciences, Inc. 89
Teijin Pharma Limited 90
Novartis AG 91
Amylin Pharmaceuticals, Inc. 92
Astellas Pharma Inc. 93
Biocon Limited 94
Chong Kun Dang Pharmaceutical 95
Chugai Pharmaceutical Co. Ltd 96
Dong-A Pharmaceutical Co., Ltd. 97
Forest Laboratories, Inc. 98
Glenmark Pharmaceuticals Ltd. 99
Ildong Pharmaceutical Co., Ltd. 100
Japan Tobacco Inc. 101
Kissei Pharmaceutical Co., Ltd. 102
Les Laboratoires Servier 103
Mitsubishi Tanabe Pharma Corporation 104
MDRNA, Inc. 105
Pfizer Inc. 106
Sigma-Tau S.p.A. 107
SuperGen, Inc. 108
VIVUS, Inc. 109
Zydus Cadila Healthcare Limited 110
Sun Pharmaceutical Industries Limited 111
Hadasit Medical Research Services & Development Ltd 112
TransPharma Medical Ltd. 113
Biodel Inc. 114
MannKind Corporation 115
Halozyme Therapeutics 116
Addex Pharmaceuticals 117
Evotec Aktiengesellschaft 118
GW Pharmaceuticals plc 119
Hollis-Eden Pharmaceuticals, Inc. 120
Enzo Biochem, Inc. 121
Genfit 122
Ligand Pharmaceuticals Incorporated 123
Lupin Limited 124
Mesoblast Ltd 125
PROLOR Biotech, Inc. 126
Oramed Pharmaceuticals, Inc. 127
Orchid Chemicals & Pharmaceuticals Ltd 128
ConjuChem Biotechnologies Inc. 129
Lexicon Pharmaceuticals, Inc. 130
Arena Pharmaceuticals, Inc. 131
Flamel Technologies S.A. 132
CSL Limited 133
ProteoTech, Inc. 134
SANWA KAGAKU KENKYUSHO CO.,LTD. 135
Yuhan Corporation 136
Unigene Laboratories, Inc. 137
XOMA Ltd. 138
Immuron Limited 139
IPCA Laboratories Limited 140
Lipoxen PLC 141
LG Life Sciences, Ltd 142
Transition Therapeutics Inc. 143
DARA BioSciences, Inc. 144
Uni-Bio Science Group Ltd. 145
Panacea Biotec Limited 146
Summit Corporation plc 147
Phynova Group Ltd 148
DiaMedica Inc. 149
NeuroVive Pharmaceutical AB 150
Debiopharm Group 151
Advinus Therapeutics Pvt. Ltd. 152
Betagenon AB 153
Chipscreen Biosciences Ltd 154
ActogeniX NV 155
Camurus AB 156
Sirtris Pharmaceuticals, Inc. 157
Evolva SA 158
reMYND 159
Metabolex, Inc 160
Celon Pharma Sp. z o.o. 161
Cortendo Invest AB 162
Spherix Incorporated 163
Curatis Pharma GmbH 164
Arisaph Pharmaceuticals, Inc. 165
AngioChem Inc. 166
Allozyne, Inc. 167
Metabolic Solutions Development Co. 168
Catabasis Pharmaceuticals, Inc. 169
PhaseBio Pharmaceuticals, Inc. 170
Five Prime Therapeutics, Inc. 171
Melior Discovery, Inc. 172
Diabetology Limited 173
Intarcia Therapeutics, Inc. 174
Theracos, Inc. 175
Versartis, Inc. 176
Kainos Medicine, Inc. 177
NOXXON Pharma AG 178
Avaxia Biologics, Inc. 179
Intercept Pharmaceuticals, Inc. 180
Omeros Corporation 181
Transtech Pharma, Inc. 182
BRIDGE BIORESEARCH PLC 183
Targacept, Inc. 184
N-Gene Research Laboratories, Inc. 185
Obio Pharmaceutical Holdings Limited. 186
ChemoCentryx, Inc. 187
VIA Pharmaceuticals, Inc. 188
USV Limited. 189
Novocell, Inc. 190
Verva Pharmaceuticals Limited 191
Napo Pharmaceuticals, Inc. 192
Medestea Research & Production S.p.A. 193
NasVax Ltd. 194
MARVEL LIFESCIENCES PRIVATE LIMITED 195
Stelic Institute & Co. 196
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 197
Adamed Sp. z o.o. 198
Regulus Therapeutics Inc. 199
Pharnext SAS 200
Ramot at Tel Aviv University Ltd. 201
Sihuan Pharmaceutical Holdings Group Ltd. 202
NGM Biopharmaceuticals, Inc. 203
The Alize Pharma Group 204
Ardelyx, Inc. 205
Heptares Therapeutics Ltd. 206
Receptos, Inc. 207
MicroDose Therapeutx, Inc. 208
Sirona Biochem Corp 209
ReceptorBio, Inc. 210
XBiotech USA, Inc. 211
Connexios Life Sciences Pvt. Ltd. 212
Serometrix, LLC 213
PharmaIN Corporation 214
Stempeutics Research Private Limited 215
Type 2 Diabetes Therapeutics Assessment 216
Assessment by Monotherapy Products 216
Assessment by Combination Products 217
Assessment by Route of Administration 218
Assessment by Molecule Type 221
Drug Profiles 224
dapagliflozin - Drug Profile 224
dapagliflozin - Drug Profile 226
saxagliptin - Drug Profile 228
teneligliptin - Drug Profile 231
dulaglutide - Drug Profile 233
tofogliflozin - Drug Profile 236
ipragliflozin - Drug Profile 237
TAK-875 - Drug Profile 240
luseogliflozin - Drug Profile 274
exenatide - Drug Profile 276
lobeglitazone - Drug Profile 278
insulin degludec - Drug Profile 279
canagliflozin - Drug Profile 282
canagliflozin - Drug Profile 284
insulin human - Drug Profile 286
insulin human - Drug Profile 288
vildagliptin + [insulin] - Drug Profile 290
insulin peglispro - Drug Profile 292
gemigliptin - Drug Profile 294
insulin degludec + [liraglutide] - Drug Profile 296
Linjeta - Drug Profile 298
MK-3102 - Drug Profile 300
(empagliflozin + linagliptin) - Drug Profile 330
lobeglitazone + [metformin hydrochloride] - Drug Profile 331
metformin hydrochloride - Drug Profile 333
(canagliflozin + metformin) IR - Drug Profile 334
(canagliflozin + metformin) IR - Drug Profile 336
CJ-30002 - Drug Profile 338
(canagliflozin + metformin) XR - Drug Profile 339
(alogliptin + metformin hydrochloride) - Drug Profile 340
Type 2 Diabetes Therapeutics Drug Profile Updates 341
Type 2 Diabetes Therapeutics Discontinued Products 390
Type 2 Diabetes Therapeutics - Dormant Products 400
Type 2 Diabetes Product Development Milestones 418
Featured News & Press Releases 418

Appendix 426
Methodology 426
Coverage 426
Secondary Research 426
Primary Research 426
Expert Panel Validation 426
Contact Us 427
Disclaimer 427

List of Table


Number of Products Under Development for Type 2 Diabetes, H1 2013 21
Products under Development for Type 2 Diabetes Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Development by Companies, H1 2013 (Contd..5) 29
Number of Products under Development by Companies, H1 2013 (Contd..6) 30
Number of Products under Development by Companies, H1 2013 (Contd..7) 31
Number of Products under Development by Companies, H1 2013 (Contd..8) 32
Number of Products under Development by Companies, H1 2013 (Contd..9) 33
Number of Products under Development by Companies, H1 2013 (Contd..10) 34
Number of Products under Development by Companies, H1 2013 (Contd..11) 35
Number of Products under Development by Companies, H1 2013 (Contd..12) 36
Number of Products under Investigation by Universities/Institutes, H1 2013 38
Comparative Analysis by Late Stage Development, H1 2013 39
Comparative Analysis by Mid Clinical Stage Development, H1 2013 40
Comparative Analysis by Early Clinical Stage Development, H1 2013 41
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 42
Products under Development by Companies, H1 2013 43
Products under Development by Companies, H1 2013 (Contd..1) 44
Products under Development by Companies, H1 2013 (Contd..2) 45
Products under Development by Companies, H1 2013 (Contd..3) 46
Products under Development by Companies, H1 2013 (Contd..4) 47
Products under Development by Companies, H1 2013 (Contd..5) 48
Products under Development by Companies, H1 2013 (Contd..6) 49
Products under Development by Companies, H1 2013 (Contd..7) 50
Products under Development by Companies, H1 2013 (Contd..8) 51
Products under Development by Companies, H1 2013 (Contd..9) 52
Products under Development by Companies, H1 2013 (Contd..10) 53
Products under Development by Companies, H1 2013 (Contd..11) 54
Products under Development by Companies, H1 2013 (Contd..12) 55
Products under Development by Companies, H1 2013 (Contd..13) 56
Products under Development by Companies, H1 2013 (Contd..14) 57
Products under Development by Companies, H1 2013 (Contd..15) 58
Products under Development by Companies, H1 2013 (Contd..16) 59
Products under Development by Companies, H1 2013 (Contd..17) 60
Products under Development by Companies, H1 2013 (Contd..18) 61
Products under Development by Companies, H1 2013 (Contd..19) 62
Products under Development by Companies, H1 2013 (Contd..20) 63
Products under Development by Companies, H1 2013 (Contd..21) 64
Products under Development by Companies, H1 2013 (Contd..22) 65
Products under Development by Companies, H1 2013 (Contd..23) 66
Products under Development by Companies, H1 2013 (Contd..24) 67
Products under Investigation by Universities/Institutes, H1 2013 68
Bristol-Myers Squibb Company, H1 2013 69
Johnson & Johnson, H1 2013 70
Boehringer Ingelheim GmbH, H1 2013 71
F. Hoffmann-La Roche Ltd., H1 2013 72
Shionogi & Co., Ltd., H1 2013 73
Medinox, Inc., H1 2013 74
Amgen Inc., H1 2013 75
Sanofi-Aventis, H1 2013 76
Eli Lilly and Company, H1 2013 77
GlaxoSmithKline plc, H1 2013 78
MedImmune LLC, H1 2013 79
Isis Pharmaceuticals, Inc., H1 2013 80
Gilead Sciences, Inc., H1 2013 81
Daiichi Sankyo Company, Ltd, H1 2013 82
Merck & Co., Inc., H1 2013 83
Dainippon Sumitomo Pharma Co., Ltd., H1 2013 84
Taisho Pharmaceutical Co., Ltd., H1 2013 85
Euroscreen S.A., H1 2013 86
Novo Nordisk A/S, H1 2013 87
Generex Biotechnology Corporation, H1 2013 88
Takeda Pharmaceutical Company Limited, H1 2013 89
FibroGen, Inc., H1 2013 90
Ipsen S.A., H1 2013 91
Senexis Limited, H1 2013 92
Nycomed International Management GmbH, H1 2013 93
Neurocrine Biosciences, Inc., H1 2013 94
Teijin Pharma Limited, H1 2013 95
Novartis AG, H1 2013 96
Amylin Pharmaceuticals, Inc., H1 2013 97
Astellas Pharma Inc., H1 2013 98
Biocon Limited, H1 2013 99
Chong Kun Dang Pharmaceutical, H1 2013 100
Chugai Pharmaceutical Co. Ltd, H1 2013 101
Dong-A Pharmaceutical Co., Ltd., H1 2013 102
Forest Laboratories, Inc., H1 2013 103
Glenmark Pharmaceuticals Ltd., H1 2013 104
Ildong Pharmaceutical Co., Ltd., H1 2013 105
Japan Tobacco Inc., H1 2013 106
Kissei Pharmaceutical Co., Ltd., H1 2013 107
Les Laboratoires Servier, H1 2013 108
Mitsubishi Tanabe Pharma Corporation, H1 2013 109
MDRNA, Inc., H1 2013 110
Pfizer Inc., H1 2013 111
Sigma-Tau S.p.A., H1 2013 112
SuperGen, Inc., H1 2013 113
VIVUS, Inc., H1 2013 114
Zydus Cadila Healthcare Limited, H1 2013 115
Sun Pharmaceutical Industries Limited, H1 2013 116
Hadasit Medical Research Services & Development Ltd, H1 2013 117
TransPharma Medical Ltd., H1 2013 118
Biodel Inc., H1 2013 119
MannKind Corporation, H1 2013 120
Halozyme Therapeutics, H1 2013 121
Addex Pharmaceuticals, H1 2013 122
Evotec Aktiengesellschaft, H1 2013 123
GW Pharmaceuticals plc, H1 2013 124
Hollis-Eden Pharmaceuticals, Inc., H1 2013 125
Enzo Biochem, Inc., H1 2013 126
Genfit, H1 2013 127
Ligand Pharmaceuticals Incorporated, H1 2013 128
Lupin Limited, H1 2013 129
Mesoblast Ltd, H1 2013 130
PROLOR Biotech, Inc., H1 2013 131
Oramed Pharmaceuticals, Inc., H1 2013 132
Orchid Chemicals & Pharmaceuticals Ltd, H1 2013 133
ConjuChem Biotechnologies Inc., H1 2013 134
Lexicon Pharmaceuticals, Inc., H1 2013 135
Arena Pharmaceuticals, Inc., H1 2013 136
Flamel Technologies S.A., H1 2013 137
CSL Limited, H1 2013 138
ProteoTech, Inc., H1 2013 139
SANWA KAGAKU KENKYUSHO CO.,LTD., H1 2013 140
Yuhan Corporation, H1 2013 141
Unigene Laboratories, Inc., H1 2013 142
XOMA Ltd., H1 2013 143
Immuron Limited, H1 2013 144
IPCA Laboratories Limited, H1 2013 145
Lipoxen PLC, H1 2013 146
LG Life Sciences, Ltd, H1 2013 147
Transition Therapeutics Inc., H1 2013 148
DARA BioSciences, Inc., H1 2013 149
Uni-Bio Science Group Ltd., H1 2013 150
Panacea Biotec Limited, H1 2013 151
Summit Corporation plc, H1 2013 152
Phynova Group Ltd, H1 2013 153
DiaMedica Inc., H1 2013 154
NeuroVive Pharmaceutical AB, H1 2013 155
Debiopharm Group, H1 2013 156
Advinus Therapeutics Pvt. Ltd., H1 2013 157
Betagenon AB, H1 2013 158
Chipscreen Biosciences Ltd, H1 2013 159
ActogeniX NV, H1 2013 160
Camurus AB, H1 2013 161
Sirtris Pharmaceuticals, Inc., H1 2013 162
Evolva SA, H1 2013 163
reMYND, H1 2013 164
Metabolex, Inc, H1 2013 165
Celon Pharma Sp. z o.o., H1 2013 166
Cortendo Invest AB, H1 2013 167
Spherix Incorporated, H1 2013 168
Curatis Pharma GmbH, H1 2013 169
Arisaph Pharmaceuticals, Inc., H1 2013 170
AngioChem Inc., H1 2013 171
Allozyne, Inc., H1 2013 172
Metabolic Solutions Development Co., H1 2013 173
Catabasis Pharmaceuticals, Inc., H1 2013 174
PhaseBio Pharmaceuticals, Inc., H1 2013 175
Five Prime Therapeutics, Inc., H1 2013 176
Melior Discovery, Inc., H1 2013 177
Diabetology Limited, H1 2013 178
Intarcia Therapeutics, Inc., H1 2013 179
Theracos, Inc., H1 2013 180
Versartis, Inc., H1 2013 181
Kainos Medicine, Inc., H1 2013 182
NOXXON Pharma AG, H1 2013 183
Avaxia Biologics, Inc., H1 2013 184
Intercept Pharmaceuticals, Inc., H1 2013 185
Omeros Corporation, H1 2013 186
Transtech Pharma, Inc., H1 2013 187
BRIDGE BIORESEARCH PLC, H1 2013 188
Targacept, Inc., H1 2013 189
N-Gene Research Laboratories, Inc., H1 2013 190
Obio Pharmaceutical Holdings Limited., H1 2013 191
ChemoCentryx, Inc., H1 2013 192
VIA Pharmaceuticals, Inc., H1 2013 193
USV Limited., H1 2013 194
Novocell, Inc., H1 2013 195
Verva Pharmaceuticals Limited, H1 2013 196
Napo Pharmaceuticals, Inc., H1 2013 197
Medestea Research & Production S.p.A., H1 2013 198
NasVax Ltd., H1 2013 199
MARVEL LIFESCIENCES PRIVATE LIMITED, H1 2013 200

List of Chart


Number of Products under Development for Type 2 Diabetes, H1 2013 21
Products under Development for Type 2 Diabetes Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 37
Late Stage Products, H1 2013 39
Mid Clinical Stage Products, H1 2013 40
Early Clinical Stage Products, H1 2013 41
Discovery and Pre-Clinical Stage Products, H1 2013 42
Assessment by Monotherapy Products, H1 2013 221
Assessment by Combination Products, H1 2013 222
Assessment by Route of Administration, H1 2013 223
Assessment by Stage and Route of Administration, H1 2013 224
Assessment by Molecule Type, H1 2013 226
Assessment by Stage and Molecule Type, H1 2013 227

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *